Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment but are associated with cardiovascular toxicity, including heart failure. This review examines the cardiotoxicity of pazopanib, a VEGFR-TKI, through two case reports and explores potential mechanisms. The importance of vigilant clinical monitoring to prevent cardiac dysfunction in cancer patients receiving pazopanib is emphasized. We present two cases of acute heart failure following pazopanib treatment. Case 1 involves a comorbidity-free, 62-year-old woman with metastatic renal cell carcinoma who experienced irreversible heart failure. In case 2, a 40-year-old woman with a history of anthracycline-containing chemotherapy developed reversible left ventricular systolic dysfunction following pazopanib discontinuation. Both patients received appropriate management for their heart failure symptoms. Case 1's condition rapidly deteriorated, leading to her unfortunate demise 3 months after starting pazopanib. In contrast, case 2's cardiac function improved after discontinuing pazopanib. The advent of TKIs has revolutionized cancer treatment, but their association with cardiovascular toxicity necessitates meticulous monitoring of patients. The cases presented here highlight the importance of recognizing and managing cardiotoxicity, particularly in patients without prior cardiovascular risk factors. Understanding the underlying mechanisms and risk factors for TKI-induced heart failure is crucial to optimize patient care and treatment outcomes. Oncologists should be vigilant in identifying clinical symptoms and closely monitoring cardiac function throughout TKI therapy.

中文翻译：

---

帕唑帕尼治疗后急性心力衰竭：两例病例报告的文献综述。

酪氨酸激酶抑制剂 (TKI) 已经改变了癌症治疗，但与心血管毒性有关，包括心力衰竭。本综述通过两个病例报告检查了帕唑帕尼（一种 VEGFR-TKI）的心脏毒性，并探讨了潜在的机制。强调了警惕临床监测以预防接受帕唑帕尼的癌症患者心功能障碍的重要性。我们介绍了两例帕唑帕尼治疗后发生急性心力衰竭的病例。病例 1 是一名无合并症的 62 岁女性，患有转移性肾细胞癌，并经历了不可逆的心力衰竭。在病例 2 中，一名 40 岁女性，有接受过含蒽环类药物化疗史，在帕唑帕尼停药后出现可逆性左心室收缩功能障碍。两名患者的心力衰竭症状均得到了适当的治疗。病例1的病情迅速恶化，导致她在开始服用帕唑帕尼3个月后不幸去世。相比之下，病例2在停用帕唑帕尼后心功能得到改善。TKI 的出现彻底改变了癌症治疗，但它们与心血管毒性的关联需要对患者进行细致的监测。这里介绍的案例强调了识别和管理心脏毒性的重要性，特别是对于既往没有心血管危险因素的患者。了解 TKI 引起的心力衰竭的潜在机制和危险因素对于优化患者护理和治疗结果至关重要。在整个 TKI 治疗过程中，肿瘤科医生应警惕识别临床症状并密切监测心脏功能。